Schizophrenia Clinical Trials in Orange, California

6 studies are recruiting for schizophrenia in Orange, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

   This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Orange, California

   Locations

   19 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07105111 on ClinicalTrials.gov

2. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Local Institution - 0151, Orange, California

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

3. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Orange, California

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

4. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Local Institution - 0158, Orange, California

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

5. A Study to Evaluate the Effect of KarXT on Urological Safety

   The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   ATP Clinical Research, Orange, California

   Locations

   13 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07221877 on ClinicalTrials.gov

6. Study of ALTO-101 in Patients With Schizophrenia

   This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerabil…

   Stage

   Phase 2

   Ages

   21 to 55

   Site

   Site 5106, Orange, California

   Locations

   14 in total

   Run by

   Alto Neuroscience

   See if you can join NCT06502964 on ClinicalTrials.gov